Quanta Therapeutics

KRAS mutations and amplifications are a driver in nearly one-quarter of all cancers. Quanta Therapeutics are developing allosteric small molecules to target previously undruggable RAS mutations in difficult to treat cancers, including pancreatic, colorectal, lung and endometrial cancer types. They are applying deep biologic insight, unique protein conformation detection technology, sophisticated medicinal chemistry and clinical development expertise to advance multiple, chemically distinct KRAS inhibitor programs with differentiated mechanisms of action. Their technology and capabilities are enabling the development of best-in-class, oral, small molecules with the potential to lead the next wave of innovation in KRAS therapy.